{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:57Z","timestamp":1787020917259,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03568-2","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T11:32:15Z","timestamp":1767699135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PEAK1 promotes prostate cancer progression and docetaxel resistance by mediating the polarization of tumor-associated macrophages"],"prefix":"10.1186","volume":"31","author":[{"given":"Jianxin","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"3568_CR1","doi-asserted-by":"crossref","unstructured":"Leung DK, Wong CH, Ko IC, et al. Global trends in the incidence, mortality, and risk-attributable deaths for prostate, bladder, and kidney cancers: a systematic analysis from the global burden of disease study 2021. Eur Urol Oncol. Published online May 28, 2025.","DOI":"10.1016\/j.euo.2025.05.007"},{"issue":"50","key":"3568_CR2","doi-asserted-by":"publisher","first-page":"7225","DOI":"10.1038\/s41388-020-01496-5","volume":"39","author":"YA Wang","year":"2020","unstructured":"Wang YA, Sfakianos J, Tewari AK, Cordon-Cardo C, Kyprianou N. Molecular tracing of prostate cancer lethality. Oncogene. 2020;39(50):7225\u201338.","journal-title":"Oncogene"},{"issue":"3","key":"3568_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","volume":"85","author":"O Bratt","year":"2024","unstructured":"Bratt O, Godtman RA, Jiborn T, et al. Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men. Eur Urol. 2024;85(3):207\u201314.","journal-title":"Eur Urol"},{"issue":"2","key":"3568_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1590\/s1677-5538.ibju.2021.0091","volume":"48","author":"A Bakavicius","year":"2022","unstructured":"Bakavicius A, Marra G, Macek P, et al. Available evidence on HIFU for focal treatment of prostate cancer: a systematic review. Int Braz J Urol. 2022;48(2):263\u201374.","journal-title":"Int Braz J Urol"},{"issue":"2","key":"3568_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164\u201382.","journal-title":"Eur Urol"},{"issue":"8","key":"3568_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41585-023-00726-1","volume":"20","author":"L Germain","year":"2023","unstructured":"Germain L, Lafront C, Paquette V, et al. Preclinical models of prostate cancer\u2014modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo. Nat Rev Urol. 2023;20(8):480\u201393.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"3568_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(7):645\u201357.","journal-title":"N Engl J Med"},{"issue":"2-3","key":"3568_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10555-013-9480-2","volume":"33","author":"DL Suzman","year":"2014","unstructured":"Suzman DL, Boikos SA, Carducci MA. Bone-targeting agents in prostate cancer. Cancer Metastasis Rev. 2014;33(2\u20133):619\u201328.","journal-title":"Cancer Metastasis Rev"},{"key":"3568_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","volume":"530","author":"J Kang","year":"2022","unstructured":"Kang J, La Manna F, Bonollo F, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156\u201369.","journal-title":"Cancer Lett"},{"issue":"4","key":"3568_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474\u201389-.e.","journal-title":"Cancer Cell"},{"issue":"2-3","key":"3568_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","volume":"33","author":"Z Culig","year":"2014","unstructured":"Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 2014;33(2\u20133):413\u201327.","journal-title":"Cancer Metastasis Rev"},{"issue":"16","key":"3568_CR12","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.7150\/ijbs.73141","volume":"18","author":"F Shi","year":"2022","unstructured":"Shi F, Sun MH, Zhou Z, et al. Tumor-associated macrophages in direct contact with prostate cancer cells promote malignant proliferation and metastasis through NOTCH1 pathway. Int J Biol Sci. 2022;18(16):5994\u20136007.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3568_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-023-01442-4","volume":"16","author":"X Ye","year":"2023","unstructured":"Ye X, Huang X, Fu X, et al. Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis. J Hematol Oncol. 2023;16(1):46.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3568_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41391-019-0168-8","volume":"23","author":"P Liang","year":"2020","unstructured":"Liang P, Henning SM, Guan J, et al. Effect of dietary omega-3 fatty acids on castrate-resistant prostate cancer and tumor-associated macrophages. Prostate Cancer Prostatic Dis. 2020;23(1):127\u201335.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"3568_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.7150\/ijms.46780","volume":"17","author":"X Geng","year":"2020","unstructured":"Geng X, Chen C, Huang Y, Hou J. The prognostic value and potential mechanism of matrix metalloproteinases among prostate cancer. Int J Med Sci. 2020;17(11):1550\u201360.","journal-title":"Int J Med Sci"},{"issue":"4","key":"3568_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-020-2435-y","volume":"11","author":"R Huang","year":"2020","unstructured":"Huang R, Wang S, Wang N, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating \u03b2-catenin\/STAT3 signaling. Cell Death Dis. 2020;11(4):234.","journal-title":"Cell Death Dis"},{"key":"3568_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106427","volume":"185","author":"Y Sun","year":"2023","unstructured":"Sun Y, Cronin MF, Mendon\u00e7a MCP, Guo J, O\u2019Driscoll CM. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer. Eur J Pharm Sci. 2023;185:106427.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"3568_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006020","volume":"11","author":"S Chen","year":"2023","unstructured":"Chen S, Lu K, Hou Y, et al. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. J Immunother Cancer. 2023;11(4):e006020.","journal-title":"J Immunother Cancer"},{"key":"3568_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2024.102932","volume":"89","author":"IS Lucet","year":"2024","unstructured":"Lucet IS, Daly RJ. View from the PEAKs: insights from structural studies on the PEAK family of pseudokinases. Curr Opin Struct Biol. 2024;89:102932.","journal-title":"Curr Opin Struct Biol"},{"issue":"6","key":"3568_CR20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1158\/0008-5472.CAN-17-2873","volume":"78","author":"K Fujimura","year":"2018","unstructured":"Fujimura K, Wang H, Watson F, Klemke RL. KRAS oncoprotein expression is regulated by a self-governing eIF5A-PEAK1 feed-forward regulatory loop. Cancer Res. 2018;78(6):1444\u201356.","journal-title":"Cancer Res"},{"issue":"24","key":"3568_CR21","doi-asserted-by":"publisher","first-page":"10920","DOI":"10.1073\/pnas.0914776107","volume":"107","author":"Y Wang","year":"2010","unstructured":"Wang Y, Kelber JA, Tran Cao HS, et al. Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]. Proc Natl Acad Sci USA. 2010;107(24):10920\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"3568_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135748","volume":"10","author":"M Agajanian","year":"2015","unstructured":"Agajanian M, Campeau A, Hoover M, et al. PEAK1 acts as a molecular switch to regulate context-dependent TGF\u03b2 responses in breast cancer. PLoS ONE. 2015;10(8):e0135748.","journal-title":"PLoS ONE"},{"issue":"8","key":"3568_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-018-0817-1","volume":"9","author":"C Ding","year":"2018","unstructured":"Ding C, Tang W, Fan X, et al. Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1\/2 and JAK2 signaling. Cell Death Dis. 2018;9(8):802.","journal-title":"Cell Death Dis"},{"issue":"33","key":"3568_CR24","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1038\/s41388-021-01906-2","volume":"40","author":"S Hamalian","year":"2021","unstructured":"Hamalian S, G\u00fcth R, Runa F, et al. A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers. Oncogene. 2021;40(33):5224\u201335.","journal-title":"Oncogene"},{"issue":"8","key":"3568_CR25","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202108027","volume":"221","author":"A Zuidema","year":"2022","unstructured":"Zuidema A, Atherton P, Kreft M, et al. PEAK1 Y635 phosphorylation regulates cell migration through association with Tensin3 and integrins. J Cell Biol. 2022;221(8):e202108027.","journal-title":"J Cell Biol"},{"issue":"1","key":"3568_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-022-01349-6","volume":"15","author":"X Shi","year":"2022","unstructured":"Shi X, Yang J, Deng S, et al. TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies. J Hematol Oncol. 2022;15(1):135.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3568_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"4","key":"3568_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/pros.24290","volume":"82","author":"K Sienkiewicz","year":"2022","unstructured":"Sienkiewicz K, Yang C, Paschal BM, Ratan A. Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR. Prostate. 2022;82(4):442\u201351.","journal-title":"Prostate"},{"issue":"1","key":"3568_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40364-024-00573-1","volume":"12","author":"X Guo","year":"2024","unstructured":"Guo X, Zhang H, He C, et al. RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages. Biomark Res. 2024;12(1):29.","journal-title":"Biomark Res"},{"issue":"7","key":"3568_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.bcp.2010.06.018","volume":"80","author":"K Lee","year":"2010","unstructured":"Lee K, Kang JE, Park SK, et al. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol. 2010;80(7):982\u20139.","journal-title":"Biochem Pharmacol"},{"key":"3568_CR31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.016645","volume":"296","author":"DK Poria","year":"2021","unstructured":"Poria DK, Sheshadri N, Balamurugan K, Sharan S, Sterneck E. The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression. J Biol Chem. 2021;296:100220.","journal-title":"J Biol Chem"},{"issue":"5","key":"3568_CR32","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00535-013-0848-4","volume":"49","author":"L Chen","year":"2014","unstructured":"Chen L, Ruan Y, Wang X, et al. BAY 11\u20137082, a nuclear factor-\u03baB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells. J Gastroenterol. 2014;49(5):864\u201374.","journal-title":"J Gastroenterol"},{"key":"3568_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101495","volume":"24","author":"R Hellsten","year":"2022","unstructured":"Hellsten R, Stiehm A, Palominos M, Persson M, Bjartell A. The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells. Transl Oncol. 2022;24:101495. https:\/\/doi.org\/10.1016\/j.tranon.2022.101495.","journal-title":"Transl Oncol"},{"issue":"2","key":"3568_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406865","volume":"12","author":"L Song","year":"2025","unstructured":"Song L, Yu X, Wu Y, Zhang W, Zhang Y, Shao Y, et al. Integrin \u03b28 facilitates macrophage infiltration and polarization by regulating CCL5 to promote LUAD progression. Adv Sci. 2025;12(2):e2406865.","journal-title":"Adv Sci"},{"issue":"7","key":"3568_CR35","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.7150\/ijbs.41686","volume":"16","author":"X Lu","year":"2020","unstructured":"Lu X, Yang F, Chen D, et al. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K\/Akt signaling pathways. Int J Biol Sci. 2020;16(7):1121\u201334.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"3568_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010091","volume":"12","author":"J Ge","year":"2024","unstructured":"Ge J, Liu Y, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma. J Immunother Cancer. 2024;12(11): e010091.","journal-title":"J Immunother Cancer."},{"issue":"W1","key":"3568_CR37","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"10013","key":"3568_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387(10013):70\u201382.","journal-title":"Lancet"},{"issue":"3","key":"3568_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41419-018-0320-8","volume":"9","author":"L Huang","year":"2018","unstructured":"Huang L, Wen C, Yang X, et al. PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR\/KRas signaling axis and miR-181d. Cell Death Dis. 2018;9(3):271.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3568_CR40","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41467-025-57046-8","volume":"16","author":"X Yang","year":"2025","unstructured":"Yang X, Ma X, Zhao T, et al. Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer. Nat Commun. 2025;16(1):1871.","journal-title":"Nat Commun"},{"issue":"722","key":"3568_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abj3554","volume":"15","author":"J Hou","year":"2022","unstructured":"Hou J, Nguyen EV, Surudoi M, et al. Distinct PEAK3 interactors and outputs expand the signaling potential of the PEAK pseudokinase family. Sci Signal. 2022;15(722):eabj3554.","journal-title":"Sci Signal"},{"issue":"7","key":"3568_CR42","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00432-021-03618-2","volume":"147","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Cai C, Zhang M, et al. Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT. J Cancer Res Clin Oncol. 2021;147(7):2013\u201323.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3568_CR43","doi-asserted-by":"publisher","first-page":"12186","DOI":"10.1038\/s41598-021-91721-2","volume":"11","author":"M Park","year":"2021","unstructured":"Park M, Cho YJ, Kim B, et al. RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway. Sci Rep. 2021;11(1):12186.","journal-title":"Sci Rep"},{"issue":"14","key":"3568_CR44","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.7150\/jca.86739","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Tan W, Wang W, et al. Sema4a promotes prostate cancer invasion: involvement of tumor microenvironment. J Cancer. 2023;14(14):2633\u201343.","journal-title":"J Cancer"},{"issue":"12","key":"3568_CR45","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1158\/0008-5472.CAN-16-2797","volume":"77","author":"R Malek","year":"2017","unstructured":"Malek R, Gajula RP, Williams RD, et al. TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis. Cancer Res. 2017;77(12):3181\u201393.","journal-title":"Cancer Res"},{"issue":"1","key":"3568_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13046-019-1247-3","volume":"38","author":"MH Chien","year":"2019","unstructured":"Chien MH, Lin YW, Wen YC, et al. Targeting the SPOCK1-snail\/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. J Exp Clin Cancer Res. 2019;38(1):246.","journal-title":"J Exp Clin Cancer Res"},{"key":"3568_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bbrc.2015.08.071","volume":"465","author":"M Agajanian","year":"2015","unstructured":"Agajanian M, Runa F, Kelber JA. Identification of a PEAK1\/ZEB1 signaling axis during TGF\u03b2\/fibronectin-induced EMT in breast cancer. Biochem Biophys Res Commun. 2015;465:606\u201312.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3568_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10238-021-00761-5","volume":"22","author":"X Wang","year":"2022","unstructured":"Wang X, Zheng Y, Wang Y. PEAK1 promotes invasion and metastasis and confers drug resistance in breast cancer. Clin Exp Med. 2022;22(3):393\u2013402.","journal-title":"Clin Exp Med"},{"issue":"9","key":"3568_CR49","first-page":"1159","volume":"39","author":"Q Wang","year":"2024","unstructured":"Wang Q, Hao F, Ning L, Sun C. Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation. Histol Histopathol. 2024;39(9):1159\u201365.","journal-title":"Histol Histopathol"},{"issue":"10","key":"3568_CR50","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1158\/0008-5472.CAN-11-3552","volume":"72","author":"JA Kelber","year":"2012","unstructured":"Kelber JA, Reno T, Kaushal S, et al. KRas induces a Src\/PEAK1\/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res. 2012;72(10):2554\u201364.","journal-title":"Cancer Res"},{"issue":"3","key":"3568_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","volume":"31","author":"MC Haffner","year":"2025","unstructured":"Haffner MC, Morris MJ, Ding CC, et al. Framework for the pathology workup of metastatic castration-resistant prostate cancer biopsies. Clin Cancer Res. 2025;31(3):466\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2061.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3568_CR52","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Curr Treat Options Oncol. 2024;25(7):914\u201331. https:\/\/doi.org\/10.1007\/s11864-024-01215-2.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"3568_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151\u20134. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.032.","journal-title":"Eur Urol"},{"issue":"1","key":"3568_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02521-7","volume":"30","author":"K Zhou","year":"2025","unstructured":"Zhou K, Lu H, Wei F, Wang J, Song Z, Mao L. Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer. Eur J Med Res. 2025;30(1):238. https:\/\/doi.org\/10.1186\/s40001-025-02521-7.","journal-title":"Eur J Med Res"},{"issue":"2","key":"3568_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020440","volume":"14","author":"C Martori","year":"2022","unstructured":"Martori C, Sanchez-Moral L, Paul T, et al. Macrophages as a therapeutic target in metastatic prostate cancer: A way to overcome immunotherapy resistance? Cancers (Basel). 2022;14(2):440.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3568_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cells11010020","volume":"11","author":"F Koinis","year":"2021","unstructured":"Koinis F, Xagara A, Chantzara E, Leontopoulou V, Aidarinis C, Kotsakis A. Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives. Cells. 2021;11(1):20.","journal-title":"Cells"},{"issue":"8048","key":"3568_CR57","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637(8048):1207\u201317.","journal-title":"Nature"},{"issue":"33","key":"3568_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402903121","volume":"121","author":"G Yu","year":"2024","unstructured":"Yu G, Corn PG, Mak CSL, et al. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci USA. 2024;121(33):e2402903121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"3568_CR59","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1158\/0008-5472.CAN-20-4028","volume":"81","author":"A El-Kenawi","year":"2021","unstructured":"El-Kenawi A, Dominguez-Viqueira W, Liu M, et al. Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res. 2021;81(21):5477\u201390.","journal-title":"Cancer Res"},{"issue":"5","key":"3568_CR60","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/bjc.2017.451","volume":"118","author":"GT Lee","year":"2018","unstructured":"Lee GT, Kwon SJ, Kim J, et al. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer. 2018;118(5):670\u20138.","journal-title":"Br J Cancer"},{"issue":"7-8","key":"3568_CR61","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s10495-025-02128-7","volume":"30","author":"M Ren","year":"2025","unstructured":"Ren M, Chen LL, Jiang LY, Yu HH, Ji HZ. The CXCL8-CXCR2 axis promotes M2 macrophage polarization in ovarian cancer via RASGRP4-mediated mTOR-STAT3 signaling. Apoptosis. 2025;30(7\u20138):1839\u201351.","journal-title":"Apoptosis"},{"key":"3568_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114629","volume":"155","author":"P Yao","year":"2025","unstructured":"Yao P, Ju H, Song A, et al. Ruxolitinib suppresses tumor growth in PTEN-deficient glioblastoma by inhibiting the STAT3-PDL1 axis-mediated the M2 polarization of macrophages. Int Immunopharmacol. 2025;155:114629.","journal-title":"Int Immunopharmacol"},{"issue":"37","key":"3568_CR63","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41388-023-02781-9","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen S, Wang M, Lu T, et al. JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3\/IL-10 axis. Oncogene. 2023;42(37):2737\u201350.","journal-title":"Oncogene"},{"issue":"1","key":"3568_CR64","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1038\/s41467-024-47949-3","volume":"15","author":"M Raymant","year":"2024","unstructured":"Raymant M, Astuti Y, Alvaro-Espinosa L, et al. Macrophage-fibroblast JAK\/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Nat Commun. 2024;15(1):3593.","journal-title":"Nat Commun"},{"issue":"6","key":"3568_CR65","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41418-019-0460-0","volume":"27","author":"C Liu","year":"2020","unstructured":"Liu C, Yao Z, Wang J, et al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65\/STAT3-CSN5-PD-L1 pathway. Cell Death Differ. 2020;27(6):1765\u201381.","journal-title":"Cell Death Differ"},{"issue":"1","key":"3568_CR66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-024-02022-x","volume":"23","author":"T Redmer","year":"2024","unstructured":"Redmer T, Raigel M, Sternberg C, et al. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression. Mol Cancer. 2024;23(1):114 (Published 2024 May 29).","journal-title":"Mol Cancer"},{"issue":"1","key":"3568_CR67","doi-asserted-by":"publisher","first-page":"15624","DOI":"10.1038\/s41598-017-15934-0","volume":"7","author":"CH Tsai","year":"2017","unstructured":"Tsai CH, Tzeng SF, Hsieh SC, et al. A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. Sci Rep. 2017;7(1):15624.","journal-title":"Sci Rep"},{"issue":"11","key":"3568_CR68","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1111\/bph.15373","volume":"178","author":"RS Cavalcante","year":"2021","unstructured":"Cavalcante RS, Ishikawa U, Silva ES, et al. STAT3\/NF-\u03baB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers\/PD-L1 antibody immunomodulatory therapy in breast cancer. Br J Pharmacol. 2021;178(11):2284\u2013304.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"3568_CR69","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/0008-5472.CAN-12-1472","volume":"73","author":"DR Croucher","year":"2013","unstructured":"Croucher DR, Hochgr\u00e4fe F, Zhang L, et al. Involvement of Lyn and the atypical kinase SgK269\/PEAK1 in a basal breast cancer signaling pathway. Cancer Res. 2013;73(6):1969\u201380.","journal-title":"Cancer Res"},{"issue":"1","key":"3568_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112734","volume":"406","author":"S Yu","year":"2021","unstructured":"Yu S, Li Q, Wang Y, et al. Tumor-derived LIF promotes chemoresistance via activating tumor-associated macrophages in gastric cancers. Exp Cell Res. 2021;406(1):112734.","journal-title":"Exp Cell Res"},{"issue":"3","key":"3568_CR71","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/cdd.2012.130","volume":"20","author":"M He","year":"2013","unstructured":"He M, Wang QY, Yin QQ, et al. HIF-1\u03b1 downregulates miR-17\/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell Death Differ. 2013;20(3):408\u201318.","journal-title":"Cell Death Differ"},{"issue":"23","key":"3568_CR72","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.3390\/cells11233712","volume":"11","author":"V Mendoza-Reinoso","year":"2022","unstructured":"Mendoza-Reinoso V, Schnepp PM, Baek DY, et al. Bone marrow macrophages induce inflammation by efferocytosis of apoptotic prostate cancer cells via HIF-1\u03b1 stabilization. Cells. 2022;11(23):3712.","journal-title":"Cells"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03568-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03568-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03568-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T18:01:50Z","timestamp":1767808910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03568-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3568"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03568-2","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Xi\u2019an People\u2019s Hospital (Approval No. 2024\u2013175) and was performed following the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have agreed to the content of the manuscript and its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}